Buspirone is under clinical development by Cingulate and currently in Phase I for Anxiety Disorders. According to GlobalData, Phase I drugs for Anxiety Disorders have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Buspirone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Buspirone overview

Buspirone is under development for the treatment of anxiety disorders. It is administered through oral route in the form a tablet. The therapeutic candidate is an anxiolytic agent and is being developed based on precision timed release (PTR) drug delivery platform technology. It acts by targeting 5-hydroxytryptamine 1A (5-HT) and dopamine receptor 2 (D2).

Cingulate overview

Cingulate operates as a holding company. It develops drugs for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety associated disorders through its subsidiary. The company is headquartered in Kansas City, Kansas, the US.

For a complete picture of Buspirone’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.